Curated News
By: NewsRamp Editorial Staff
November 10, 2025

NRx Launches Revolutionary One-Day Depression Treatment in Florida

Discuss on Substack View History of this news story on GitHub
Original Source

TLDR

  • NRx Pharmaceuticals offers a competitive edge with its one-day depression treatment protocol achieving 87% response rates, positioning it ahead of traditional multi-month therapies.
  • The Ampa device combines transcranial magnetic stimulation with D-cycloserine and lisdexamfetamine in a single-day protocol that has demonstrated 72% remission rates in clinical studies.
  • This breakthrough treatment transforms mental healthcare by providing rapid relief for millions suffering from depression and PTSD, offering hope where traditional therapies have failed.
  • Florida clinics now deploy a revolutionary one-day depression treatment combining magnetic brain stimulation with medications, achieving results previously requiring months of therapy.

Impact - Why it Matters

This development matters because treatment-resistant depression affects millions worldwide who often cycle through multiple medications and therapies without success, leading to devastating personal, social, and economic consequences. The traditional TMS treatment regimen requiring daily sessions over several months creates significant barriers to access, including time away from work, transportation challenges, and substantial financial burden. By condensing treatment into a single day while maintaining high efficacy rates, this innovation could dramatically improve accessibility and reduce the overall burden on patients and healthcare systems. For the estimated 30% of depression patients who don't respond to conventional treatments, this represents a potential life-changing breakthrough that could restore functionality and quality of life much more rapidly than current options allow.

Summary

NRx Pharmaceuticals (NASDAQ: NRXP) has achieved a significant breakthrough in mental health treatment through its subsidiary HOPE Therapeutics™, which has initiated patient care using the revolutionary Ampa "one day" (ONE-D) protocol for treatment-resistant depression. This marks the first deployment of its kind in Florida and among the earliest nationwide implementations. The innovative protocol combines a single day of transcranial magnetic stimulation (TMS) with physician-prescribed D-cycloserine and lisdexamfetamine, representing a dramatic departure from traditional TMS therapy that typically requires months of treatment. Under the expert direction of Medical Director Dr. Rebecca Cohen, HOPE clinics in Sarasota, Naples, and Fort Myers are now offering this groundbreaking approach, with plans to expand to six Florida locations by year-end. The treatment has demonstrated remarkable efficacy in peer-reviewed studies, showing response rates of 87% and remission rates of 72% in nonrandomized trials, offering new hope for patients who have struggled with conventional depression treatments.

The broader context reveals NRx Pharmaceuticals as a clinical-stage biopharmaceutical company developing cutting-edge therapeutics based on its NMDA platform for central nervous system disorders, including suicidal depression, chronic pain, and PTSD. The company's pipeline includes NRX-100, a preservative-free intravenous ketamine that has received Fast Track Designation for treating Suicidal Ideation in Depression, and NRX-101, an oral combination of D-cycloserine and lurasidone that has been awarded Breakthrough Therapy Designation for suicidal bipolar depression. NRx has recently filed both an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application for NRX-100, with an application for the Commissioner's National Priority Voucher Program specifically targeting suicidal depression treatment. This comprehensive approach to mental health innovation represents a significant advancement in the field, potentially transforming how severe depression and related conditions are managed clinically.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NRx Launches Revolutionary One-Day Depression Treatment in Florida

blockchain registration record for this content.